| Betaseron (IFN-β-1b) / Bayer |
NCT00439257: Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron) |
|
|
| Completed | N/A | 124 | US | | US Department of Veterans Affairs | Multiple Sclerosis | | 06/00 | | |
NCT00206635: Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis |
|
|
| Completed | N/A | 432 | US, Canada | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis | | 12/05 | | |
NCT00490906: Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis |
|
|
| Completed | N/A | 60 | US | Copaxone, Glatiramer acetate, Interferon-beta 1a, Avonex, Interferon-beta 1b, Betaseron | Nancy Hammond, MD, Kansas City Area Life Sciences Institute, Inc. | Multiple Sclerosis, Low Bone Density | 02/09 | 12/12 | | |
NCT01233245: BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program |
|
|
| Completed | N/A | 1077 | Europe, RoW | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS) | 06/09 | 06/09 | | |
NCT00461396: Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron |
|
|
| Completed | N/A | 104 | US | Interferon-1beta (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | 06/09 | 11/09 | | |
ROBUST, NCT01158183: Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis |
|
|
| Completed | N/A | 226 | US | BAY86-5046_Interferon-beta-1b | Bayer | Multiple Sclerosis, Relapsing-Remitting | 09/09 | 09/09 | | |
NCT00928967: Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients |
|
|
| Completed | N/A | 67 | Europe | Interferon beta-1b, (Betaseron BAY86-5046) | Bayer | Multiple Sclerosis | 03/10 | 11/10 | | |
NCT01031459: Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial. |
|
|
| Completed | N/A | 176 | US, Canada | Betaseron (Interferon beta-1b, BAY86-5046) | Bayer | Multiple Sclerosis | 12/10 | 12/10 | | |
| Completed | N/A | 283 | Canada, Europe, RoW | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis | 01/11 | 01/11 | | |
|
|
|
NCT00873340: Physical Disability in Patients Treated With Betaferon |
|
|
| Completed | N/A | 83 | RoW | Interferon-1beta (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis | 01/11 | 01/11 | | |
| Completed | N/A | 1739 | Canada, Europe, RoW | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis | 03/11 | 03/11 | | |
POR-BetaPlus, NCT01235455: Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors |
|
|
| Completed | N/A | 10 | Europe | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) | | 05/11 | | |
BREAK, NCT01184833: Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis |
|
|
| Completed | N/A | 852 | Europe | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis | | 08/11 | | |
NCT00468182: Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis |
|
|
| Completed | N/A | 24 | US | Interferon-beta 1b (Betaseron) | Rutgers, The State University of New Jersey, Bayer | Multiple Sclerosis | 12/11 | 12/11 | | |
| Completed | N/A | 113 | US | | Syneos Health, Bayer | Birth Defects, Pregnancy Complications, Multiple Sclerosis | 04/12 | 06/12 | | |
|
NCT01122056: Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis |
|
|
| Completed | N/A | 128 | Canada | Physical exercise training, Betaseron b1b-interferon, Aerobic exercise | University of British Columbia, Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma | Multiple Sclerosis | 06/12 | 06/12 | | |
NCT01414816: Betaferon® Regulatory Post-Marketing Surveillance |
|
|
| Completed | N/A | 355 | RoW | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis, Clinically Isolated System | 07/12 | 07/12 | | |
| Completed | N/A | 2878 | US | Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b, Copaxone®, Avonex®, Rebif®, Betaseron® | Teva Neuroscience, Inc. | Multiple Sclerosis | 12/12 | 01/13 | | |
|
|
|
|
|
|
|
|
NCT01071694: QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea |
|
|
| Withdrawn | N/A | 0 | RoW | Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis, Relapsing-Remitting | 12/12 | 12/12 | | |
NCT01354665: Depression and Fatigue in MS Patients Treated With Betaferon. |
|
|
| Completed | N/A | 567 | Europe | Interferon beta-1b (Betaferon, BAY86-5046) | Bayer | Multiple Sclerosis | 06/13 | 06/13 | | |
BEACON, NCT00787657: Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment |
|
|
| Completed | N/A | 1723 | Canada, Europe, RoW | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Relapsing Remitting Multiple Sclerosis (RRMS) | 09/13 | 10/14 | | |
SEPLUS, NCT01076595: Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period |
|
|
| Completed | N/A | 73 | Europe | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis | 11/13 | 07/14 | | |
NCT00902135: Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) |
|
|
| Completed | N/A | 702 | Europe | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Relapsing-Remitting Multiple Sclerosis | 12/13 | 08/14 | | |
NCT01436838: China Betaferon Adherence, Coping and Nurse Support Study |
|
|
| Completed | N/A | 110 | RoW | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis, Chronic Progressive | 09/15 | 12/15 | | |
NCT01706055: Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) |
|
|
| Completed | N/A | 629 | Europe | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis | 09/15 | 03/16 | | |
| Completed | N/A | 151 | Europe | Interferon beta-1b (Betaferon, BAY 86-5046), BETACONNECT auto-injector. | Bayer | Multiple Sclerosis | 03/16 | 06/16 | | |
NCT00963833: Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis |
|
|
| Completed | N/A | 68 | Europe, RoW | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis | 04/16 | 09/16 | | |
NCT02247310: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon |
|
|
| Completed | N/A | 498 | Europe, RoW | Interferon beta-1b (Betaferon®, BAY 86-5046), BETACONNECT | Bayer | Multiple Sclerosis, Relapsing Remitting | 07/16 | 11/16 | | |
NCT01491100: Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis |
|
|
| Completed | N/A | 1085 | Europe, RoW | Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Multiple Sclerosis | 12/16 | 04/17 | | |
BetaSleep, NCT01766063: Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon |
|
|
| Completed | N/A | 138 | Europe | Interferon beta-1b (Betaferon, BAY 86-5046) | Bayer | Multiple Sclerosis | 01/17 | 03/17 | | |
NCT02652091: Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction |
|
|
| Completed | N/A | 146 | US | Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device | Bayer | Multiple Sclerosis, Relapsing-Remitting | 08/17 | 09/17 | | |
PROmyBETAapp, NCT03134573: Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study |
|
|
| Completed | N/A | 96 | Europe | Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp | Bayer | Multiple Sclerosis | 05/18 | 05/18 | | |
